Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study.

Introduction: Maintaining or improving health-related quality of life (HRQoL) is as important as extending survival in metastatic colorectal cancer. We report an HRQoL analysis from FRESCO-2 (NCT04322539).

Methods: Patients were randomized to fruquintinib +best supportive care (BSC; n = 461) or placebo +BSC (n = 230).